{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:51:30Z","timestamp":1792695090815,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82161138021"],"award-info":[{"award-number":["82161138021"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005713","name":"Technical University of Munich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["82161138021"],"award-info":[{"award-number":["82161138021"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["468853597"],"award-info":[{"award-number":["468853597"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202108440074"],"award-info":[{"award-number":["202108440074"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.euroneuro.2025.02.012","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T21:42:50Z","timestamp":1741470170000},"page":"51-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Antipsychotic drug dosing and study discontinuation in schizophrenia: A systematic review and dose-response meta-analysis"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-3538","authenticated-orcid":false,"given":"Jing","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8264-2039","authenticated-orcid":false,"given":"Spyridon","family":"Siafis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3448-9532","authenticated-orcid":false,"given":"Johannes","family":"Schneider-Thoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4523-7317","authenticated-orcid":false,"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2025.02.012_bib0001","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.4088\/JCP.v69n1105","article-title":"Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg\/day vs. 400 mg\/day of quetiapine fumarate in 141 patients aged 15 to 25 years","volume":"69","author":"Berger","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0002","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1192\/bjp.166.1.68","article-title":"Treatment of negative symptoms in schizophrenia with amisulpride","volume":"166","author":"Boyer","year":"1995","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0003","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/schbul\/sbac041","article-title":"Maintenance treatment with antipsychotic drugs in schizophrenia: a Cochrane Systematic review and Meta-analysis","volume":"48","author":"Ceraso","year":"2022","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0004","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0005","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12325-013-0006-7","article-title":"Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy","volume":"30","author":"Citrome","year":"2013","journal-title":"Adv. Ther."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0006","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/hup.1254","article-title":"Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo-and active-controlled trials","volume":"27","author":"Citrome","year":"2012","journal-title":"Human Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0007","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1034\/j.1600-0447.2000.101003218.x","article-title":"A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia","volume":"101","author":"Cooper","year":"2000","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0008","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jamapsychiatry.2019.4379","article-title":"Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial","volume":"77","author":"Correll","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0009","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.schres.2016.04.012","article-title":"Efficacy of brexpiprazole in patients with acute schizophrenia: review of three randomized, double-blind, placebo-controlled studies","volume":"174","author":"Correll","year":"2016","journal-title":"Schizophrenia Res."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0010","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1176\/appi.ajp.2015.14101275","article-title":"Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial","volume":"172","author":"Correll","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0011","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1177\/0962280218773122","article-title":"One-stage dose-response meta-analysis for aggregated data","volume":"28","author":"Crippa","year":"2019","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v072.c01","article-title":"Multivariate dose-response meta-analysis: the dosresmeta R package","volume":"72","author":"Crippa","year":"2016","journal-title":"J. Stat. Soft."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0013","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/JCP.0b013e318169d4ce","article-title":"Four-week, double-blind, placebo-and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia","volume":"28","author":"Cutler","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0014","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1176\/ajp.156.4.610","article-title":"Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride","volume":"156","author":"Danion","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0015","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.schres.2007.12.475","article-title":"Antipsychotic treatment patterns and hospitalizations among adults with schizophrenia","volume":"101","author":"dosReis","year":"2008","journal-title":"Schizophrenia Res."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0016","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.4088\/JCP.15m09997","article-title":"Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo-and active-controlled trial","volume":"76","author":"Durgam","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0017","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","article-title":"An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial","volume":"152","author":"Durgam","year":"2014","journal-title":"Schizophrenia Res."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0018","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/cap.2015.0027","article-title":"Safety and efficacy from an 8 week double-blind trial and a 26 week open-label extension of asenapine in adolescents with schizophrenia","volume":"25","author":"Findling","year":"2015","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0019","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/cap.2011.0092","article-title":"Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial","volume":"22","author":"Findling","year":"2012","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0020","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia","volume":"165","author":"Findling","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0021","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/00023210-200923070-00006","article-title":"The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study","volume":"23","author":"Garcia","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0022","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1089\/cap.2016.0189","article-title":"Efficacy and safety of Lurasidone in adolescents with schizophrenia: a 6-week, randomized placebo-controlled study","volume":"27","author":"Goldman","year":"2017","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0023","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1192\/bjp.bp.107.046177","article-title":"Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study","volume":"194","author":"Haas","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0024","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/cap.2008.0144","article-title":"A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia","volume":"19","author":"Haas","year":"2009","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0025","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Stat. Med."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0027","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0028","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/pcn.12682","article-title":"Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: a 6-week, randomized, double-blind, placebo-controlled study","volume":"72","author":"Ishigooka","year":"2018","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0029","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.schres.2019.07.055","article-title":"Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: a 6-week randomized, double-blind, placebo-controlled, multicenter study. 0920-9964","volume":"215","author":"Iwata","year":"2020","journal-title":"Schizophrenia Res."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0030","doi-asserted-by":"crossref","first-page":"15067","DOI":"10.1038\/nrdp.2015.67","article-title":"Schizophrenia","volume":"1","author":"Kahn","year":"2015","journal-title":"Nat. Rev. Dis Primers"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0031","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2015.01.038","article-title":"A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia","volume":"164","author":"Kane","year":"2015","journal-title":"Schizophrenia Res."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0032","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial","volume":"35","author":"Kane","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0033","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1001\/jamapsychiatry.2023.2983","article-title":"Efficacy and safety of antidepressants in patients with comorbid depression and medical diseases: an umbrella systematic review and meta-analysis","volume":"80","author":"K\u00f6hler-Forsberg","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0034","series-title":"A Multicenter, Double-blind, Randomized, Dose-comparison Study of Three Different Doses of Aripiprazole (2 mg\/Day, 6-12 mg\/Day, 24-30 mg\/Day) Orally Administered Over 6 Weeks in Pediatric Patients (Aged 13-17 Years) With Schizophrenia","author":"Imaoka","year":"2017"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0035","doi-asserted-by":"crossref","first-page":"994","DOI":"10.4088\/JCP.v62n1214c","article-title":"A pilot double-blind, dose-comparison study of risperidone in drug-naive, first-episode schizophrenia","volume":"62","author":"Lane","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0036","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1600-0447.2006.00887.x","article-title":"The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial","volume":"114","author":"Lecrubier","year":"2006","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0037","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1600-0447.2006.00887.x","article-title":"The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial","volume":"114","author":"Lecrubier","year":"2006","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0038","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11113070","article-title":"Antipsychotics: 70 years","volume":"11","author":"Lentini","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0039","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","article-title":"Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia","volume":"177","author":"Leucht","year":"2020","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl 5","key":"10.1016\/j.euroneuro.2025.02.012_bib0040","first-page":"3","article-title":"Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia","volume":"67","author":"Leucht","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0041","doi-asserted-by":"crossref","first-page":"0920","DOI":"10.1016\/j.schres.2022.01.001","article-title":"About the issue of including or excluding studies from China in systematic reviews","volume":"240","author":"Leucht","year":"2022","journal-title":"Schizophrenia Res."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0042","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0043","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopsych.2015.08.026","article-title":"ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial","volume":"79","author":"Lieberman","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0044","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0045","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1192\/bjp.170.1.18","article-title":"Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia","volume":"170","author":"Loo","year":"1997","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0046","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/pcn.12681","article-title":"Safety and efficacy from a 6-week double-blind study and a 52-week open-label extension of aripiprazole in adolescents with schizophrenia in Japan","volume":"72","author":"Matsumoto","year":"2018","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0047","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s40265-015-0494-7","article-title":"Cariprazine: first global approval","volume":"75","author":"McCormack","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0048","doi-asserted-by":"crossref","first-page":"885","DOI":"10.4088\/JCP.v63n1006","article-title":"Risperidone, 2 mg\/day vs. 4 mg\/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning","volume":"63","author":"Merlo","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0049","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/DDDT.S95100","article-title":"Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)","volume":"10","author":"Nakamura","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0050","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/S1461145704004262","article-title":"A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis","volume":"7","author":"Oosthuizen","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0051","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.4088\/JCP.v69n1004","article-title":"A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: depot versus oral","volume":"69","author":"Patel","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0052","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry","volume":"61","author":"Peters","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0053","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12769","article-title":"Efficacy and safety of a combination of olanzapine and samidorphan in adult patients with an acute exacerbation of schizophrenia: outcomes from the randomized, phase 3 Enlighten-1 study","volume":"81","author":"Potkin","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0054","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/JCP.0b013e3181692787","article-title":"Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies","volume":"28","author":"Potkin","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0055","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0447.1998.tb10044.x","article-title":"Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group","volume":"98","author":"Puech","year":"1998","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0056","article-title":"Antipsychotic dose reduction compared to dose continuation for people with schizophrenia","volume":"11","author":"Rodolico","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0057","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1089\/cap.2021.0013","article-title":"Efficacy and safety of Blonanserin oral tablet in adolescents with schizophrenia: a 6-week, randomized placebo-controlled study","volume":"32","author":"Saito","year":"2022","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0058","first-page":"753","article-title":"Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis. The lancet","volume":"6","author":"Schneider-Thoma","year":"2019","journal-title":"Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0059","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.psychres.2014.11.002","article-title":"A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders","volume":"225","author":"Sendt","year":"2015","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0060","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1038\/s41380-023-02203-y","article-title":"Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis","volume":"28","author":"Siafis","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0061","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1176\/ajp.156.11.1744","article-title":"Double-blind study of clozapine dose response in chronic schizophrenia","volume":"156","author":"Simpson","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0062","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.biopsych.2011.06.021","article-title":"A randomized, double-blind study of paliperidone extended-release in t reatment of acute schizophrenia in adolescents","volume":"70","author":"Singh","year":"2025","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0063","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12874-018-0554-2","article-title":"Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China national knowledge infrastructure (CNKI): a literature and telephone interview study","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0064","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/14656566.2019.1695778","article-title":"An evaluation of lumateperone tosylate for the treatment of schizophrenia","volume":"21","author":"Vyas","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0065","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/schbul\/sbad089","article-title":"Long-acting injectable second-generation antipsychotics vs placebo and their oral formulations in acute schizophrenia: a systematic review and meta-analysis of randomized-controlled-trials","volume":"50","author":"Wang","year":"2024","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0066","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/JCP.0b013e3181694f5a","article-title":"Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials","volume":"28","author":"Weiden","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0067","first-page":"197","article-title":"Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST). The lancet","volume":"10","author":"Winter-van Rossum","year":"2023","journal-title":"Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0068","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/schbul\/sbac001","article-title":"Antipsychotic-induced weight gain: dose-response meta-analysis of randomized controlled trials","volume":"48","author":"Wu","year":"2022","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2025.02.012_bib0069","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.euroneuro.2023.03.015","article-title":"Antipsychotic-induced akathisia in adults with acute schizophrenia: a systematic review and dose-response meta-analysis","volume":"72","author":"Wu","year":"2023","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X25000446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X25000446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T15:53:57Z","timestamp":1746806037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X25000446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":68,"alternative-id":["S0924977X25000446"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.02.012","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipsychotic drug dosing and study discontinuation in schizophrenia: A systematic review and dose-response meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}